Cargando…
Insulin resistance in COVID-19 and diabetes
BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Primary Care Diabetes Europe. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031259/ https://www.ncbi.nlm.nih.gov/pubmed/33849817 http://dx.doi.org/10.1016/j.pcd.2021.04.004 |
_version_ | 1783676143172321280 |
---|---|
author | Govender, Nalini Khaliq, Olive P. Moodley, Jagidesa Naicker, Thajasvarie |
author_facet | Govender, Nalini Khaliq, Olive P. Moodley, Jagidesa Naicker, Thajasvarie |
author_sort | Govender, Nalini |
collection | PubMed |
description | BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was done via PubMed and Google Scholar using the MeSH terms “COVID-19,” “SARS-CoV-2,” “coronavirus,” “insulin resistance,” and “diabetes.” Only articles that were directly applicable to insulin resistance in COVID-19 and diabetes was reviewed. RESULTS: Current data shows an increased risk of mortality in patients with diabetes and COVID-19 compared to those without diabetes. COVID-19 triggers insulin resistance in patients, causing chronic metabolic disorders that were non-existent prior to infection. CONCLUSION: Patients with diabetes are more susceptible to COVID-19 infection than those without diabetes. ACE2 expression decreases with infection, exaggerating Ang II activity with subsequent insulin resistance development, an exaggerated immune response and severe SARS-COV-2 infection. |
format | Online Article Text |
id | pubmed-8031259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Primary Care Diabetes Europe. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80312592021-04-09 Insulin resistance in COVID-19 and diabetes Govender, Nalini Khaliq, Olive P. Moodley, Jagidesa Naicker, Thajasvarie Prim Care Diabetes Review BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was done via PubMed and Google Scholar using the MeSH terms “COVID-19,” “SARS-CoV-2,” “coronavirus,” “insulin resistance,” and “diabetes.” Only articles that were directly applicable to insulin resistance in COVID-19 and diabetes was reviewed. RESULTS: Current data shows an increased risk of mortality in patients with diabetes and COVID-19 compared to those without diabetes. COVID-19 triggers insulin resistance in patients, causing chronic metabolic disorders that were non-existent prior to infection. CONCLUSION: Patients with diabetes are more susceptible to COVID-19 infection than those without diabetes. ACE2 expression decreases with infection, exaggerating Ang II activity with subsequent insulin resistance development, an exaggerated immune response and severe SARS-COV-2 infection. Primary Care Diabetes Europe. Published by Elsevier Ltd. 2021-08 2021-04-08 /pmc/articles/PMC8031259/ /pubmed/33849817 http://dx.doi.org/10.1016/j.pcd.2021.04.004 Text en © 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Govender, Nalini Khaliq, Olive P. Moodley, Jagidesa Naicker, Thajasvarie Insulin resistance in COVID-19 and diabetes |
title | Insulin resistance in COVID-19 and diabetes |
title_full | Insulin resistance in COVID-19 and diabetes |
title_fullStr | Insulin resistance in COVID-19 and diabetes |
title_full_unstemmed | Insulin resistance in COVID-19 and diabetes |
title_short | Insulin resistance in COVID-19 and diabetes |
title_sort | insulin resistance in covid-19 and diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031259/ https://www.ncbi.nlm.nih.gov/pubmed/33849817 http://dx.doi.org/10.1016/j.pcd.2021.04.004 |
work_keys_str_mv | AT govendernalini insulinresistanceincovid19anddiabetes AT khaliqolivep insulinresistanceincovid19anddiabetes AT moodleyjagidesa insulinresistanceincovid19anddiabetes AT naickerthajasvarie insulinresistanceincovid19anddiabetes |